Predictive health company Sema4 and VieCure said they have launched a precision oncology collaboration designed to improve the diagnosis, treatment, and prevention of cancer by integrating patient data, predictive modeling, access to genetic screening, and information about clinical trials.
The collaboration, whose value was not disclosed, is designed to integrate insights generated from patient data—furnished by consent, the companies stressed—by combining Sema4’s Centrellis™ health intelligence platform with VieCure’s VCurePrecision™ EMR platform. Those insights are intended to support point-of-care decision making by oncologists.
The collaboration is also intended to allow healthcare providers to order Sema4’s molecular testing for cancer through VCurePrecision, giving them easier access to Sema4’s genetic screening. Test results will be shared with healthcare providers through VCurePrecision, which also identifies genetic counseling options available to patients as well as available clinical trials.
“Our system combines patient data with leading scientific knowledge to generate and manage individualized treatment plans throughout the patient’s diagnosis and care journey,” Fred Ashbury, Ph.D., VieCure’s chief scientific officer, said in a statement. “We are excited to deliver even better insights to the providers who use our smart EMR through Sema4’s deep knowledge of multi-dimensional data analysis, predictive modeling, and advanced genetic testing.”
VCurePrecision is an AI-enabled point-of-care solution designed to collect, curate, and streamline information such as imaging, molecular testing, and patient-reported outcomes for tens of thousands of patients. The system also incorporates genetic and genomic data, such as results from next-generation sequencing tests, and includes a consent process so patients can be directly recruited into clinical trials within the VieCure workflow.
The real-time decision support system assists oncologists and hematologists in generating personalized treatment plans and managing a patient’s treatment throughout diagnosis, cancer therapy, and ongoing follow-up care. VieCure said the platform has been implemented in private practice cancer centers and large provider organizations.
“By teaming up with VieCure, we are able to partner with oncologists and healthcare systems to offer a full cancer care platform that includes real-time point-of-care precision oncology insights, research support, and clinical trial recruitment,” added James Coffin, Ph.D., president and chief operating officer of Sema4. “This collaboration builds on our commitment to use the latest advances in genomics and real-world clinical data to give oncologists and their patients a critical edge in battling cancer.”